secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009829
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma reports setrusumab Phase 3 miss; extends cash runway to mid-2027
--------------------------------------------------------------------------------

- Cash and equivalents $41M as of Dec 31, 2025; reduced pre-commercial spend extends runway to mid-2027.
- Setrusumab Phase 3 Orbit/Cosmic missed primary fracture-rate endpoints; BMD secondary endpoint met (p<0.001).
- Alvelestat Phase 3 plan: single 220-patient trial over 18 months; partnering discussions ongoing.
- Vantictumab out-licensed to ashibio for ADO2; Phase 2 expected 2H 2026; Mereo retains EU rights.
- No approved OI therapies in US/EU except Italy's neridronate; high unmet need remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526009829/0001193125-26-009829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526009829/mreo-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer